The team also explored potential interventions to prevent the development of generalized fear. They found that administering an adeno-associated virus (AAV) to suppress the gene responsible for GABA ...

PHILADELPHIA, PA — Passage Bio, Inc. has unveiled promising interim data from its ongoing global Phase 1/2 upliFT-D clinical ...

Scientists have developed new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer's disease, and improve symptoms of neurodegeneration in mice.

Investigating ECM changes in the hypothalamus reveals mechanisms behind insulin resistance, offering insights into obesity ...

Immunosuppressants used in adeno-associated virus (AAV) gene therapy for monogenic disorders present an adverse effect ...

A new study describes the use of artificial intelligence (AI) in designing a new generation of capsids, the structures that ...

Among the Wall Street firms investors often pay closest attention to, Goldman Sachs (NYSE:GS) has to be atop the list. The ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) released topline results from the Phase 1/2 open-label ADventure study of BBP-631, an ...

Previous efforts to circumvent the problem of the size limitation imposed by the AAV vector have focused mainly on altering the candidate genes into ‘mini-expression cassettes’ suitable for ...

Scientists from Spirovant Sciences describe SP-101, a novel adeno-associated virus (AAV) gene therapy for the treatment of ...

Researchers have discovered that remodeling of extracellular matrix (ECM) in the hypothalamus, specifically around AgRP ...

Clinical decision-making can be difficult for patients with SMA due to the lack of clinical trials comparing treatment ...